The application of 'reverse genetics' procedures has led to the successful isolation of genes responsible for human genetic disease in recent years. It is now commonplace, in the UK at least, for these genes to be used in prenatal screening programmes to determine mutant gene carrier status in families. The advantage of using the causative gene is that the chances of recombination between marker and phenotype are very small. However, despite the relative success in the isolation of genes responsible for biochemical disorders such as PKU, thalassemia, and many other genetic diseases there have been few genes isolated and characterised which are responsible for hereditary predisposition to cancer. The first, and still most extensively -studied, cancer predisposition gene to be isolated was the retinoblastoma gene, RB1 (Friend et al., 1986) .
Retinoblastoma (Rb) is an intraocular tumour of children which has both hereditary and sporadic forms (Vogel, 1979; Cowell, 1991) . Only 15% of patients have a positive family history although all bilateral cases (around 40%) are generally considered to be germ line carriers of a predisposing mutation (Knudson, 1971) . The Rb phenotype segregates as an autosomal dominant trait with high penetrance (Vogel, 1979 (Wiggs et al., 1988) . These probes form the basis of linkage studies in the analysis of Rb families worldwide and have been successfully applied in 80-90% of families (Wiggs et al., 1988; Scheffer et al., 1989; Onadim et al., 1990) . More recently other RFLPs and DNA sequence polymorphisms McGee et al., 1989) have been added to the armoury of probes available. In cases of familial Rb, it is now possible to establish with which chromosome the mutant allele segregates using standard linkage studies (Cowell et al., 1986; All of the procedures for the RFLP analysis using the probes RS2.0, PRO.6 (Wiggs et al., 1988) and M1.8 (Bookstein et al., 1988) were as described previously . The procedures for PCR based detection of polymorphic sites have been described in .
The RB1.20 polymorphism consists of a variable number of {CTTT(T))} (n = 14-26) repeats and occurs 54 bp from the 3' end of exon 20.
The two primers used to amplify the RB1.20 polymorphism were: 5' Primer 5'-GTATGAACTCATGAGACAGGCAT-3' 3' Primer 5'-AATTAACAAGGTGTGGTGGTACACG-3' We tested a series of primers to amplify this region and found this particular pair to give the best results. These are not the same primers originally used by (Wigg et al., 1988; Bookstein et al., 1988) . The Ml.8 probe recognises two variant alleles, the first is 4.5 kb long and the second consists of a doublet 2.3 kb + 2.2 kb. For simplicity heterozygous individuals are described throughout as 4.5/2.3 (instead of 4.5/2.3 + 2.2) (Figure 1 ). Homozygous individuals for the lower allele are described as 2.3/2.3 (instead of 2.3 + 2.2/2.3 + 2.2). The conventional way of identifying RFLPs using PRO.6 and Ml.8 is by Southern blotting . However, the same polymorphisms can also be detected using PCR techniques (McGee et al., 1990; Bookstein et al., 1990; where the allele sizes depend on the specific oligonucleotides used. In PCR analysis it is the presence or absence of the appropriate restriction enzyme site which defines the polymorphism. In our study, which method was used depended on the availability of DNA. Using the RB1.20 VNTR 94% of individuals were reported to be heterozygous (informative) at this locus but only 28 families were studied and these do not represent a random sample since they were chosen because they were uninformative using the majority of the other intragenic DNA probes.
The pedigrees from all of the families for whom presymptomatic screening was undertaken is given in Figure 1 . In Table I , the result of each presymptomatic screening carried out was given for each family, together with the age at testing, current age and the informative probes used. Screening followed the conventional protocol of examination, under anaesthesia, of the retinae of both eyes every 3 months to the age of 2, 4 months to the age of 3 and 6 months to the age of 5. In all, four prenatal and six post-natal tests were carried out. Of these, only one was found to have inherited the mutant RB1 gene (Figure 2 ). The first ever prenatal prediction within an RB family (RBF 14) In family RBF06 (Figure 1 ) post-natal screening of II.2 after 16 months and prenatal screening of II.3 showed that neither inherited the mutant Rb gene, co-segregating with the 1.65 kb, RS2.0 allele from the affected father. This result was confirmed using the M1.8 probe. Both II.2 and II.3 were homozygous for the 2.3 kb allele whereas the RB predisposition clearly segregates with the 4.5 kb allele in this family.
In our experience families are usually only informative for a few of the RFLPs. Clearly, the more probes that can be used the more confident our predictions will be. In RBF06
we were able to confirm the results with a third polymorphism, the RBl.20 VNTR. In this analysis, Rb predisposition segregates with allele 5 in the family and, although no DNA was available from 11.2, II.3 was not shown to inherit this allele.
In family RBF13 (Figure 1 ) a post natal screen of II.2 was undertaken when the child was 6 months old (reported in Onadim et al., 1991) and, subsequently, a second post-natal screen was performed after 0.5 months for II.3. Neither child inherited the allele associated with Rb predisposition (1.95 kb with RS2.0 and allele 2 with RB1.20).
Family RBF29 (Figure 1 ) has an unusual inheritance pattern which was described by where the possibility of future prenatal screening was indicated. In March 1991 we analysed a CV sample from the fetus (III.5) who was found not to carry the Rb predisposition allele (1.9 kb RS2.0; allele 6 RB1.20). Later, the predisposing mutation itself was identified in this family. All the affected individuals and unaffected gene carriers were found to carry this mutation. The mutation was not present in III.5 (Onadim et al., submitted).
In family RBF22 (Figure 1) , the Rb mutation is segregating with the 1.95 kb allele identified by RS2.0 and the 6.5 kb allele identified by PRO.6 Figure 1 The pedigrees of the families for whom presymptomatic screening was undertaken. For each individual the size or the number of alleles(s) for each informative polymorphism are given. An arrow / indicates the individuals for whom a presumptomatic prediction was given. III.3 was found not to have inherited the 1.95 allele and therefore is expected to be unaffected. Family RBF33 (Figure 1) was not informative for three of the probes used in our screening programme, i.e. RS2.0, PR0.6 and M1.8. They were, however, informative for the polymorphism RB1.20. Using DNA from a cord blood sample, III.1 was shown to have inherited the mutant Rb predisposition gene segregating with allele 3 (Figure 2 ) in this family. Two weeks later, ophthalmological examination of III.1 identified tumours in both eyes.
Family RBF34 (Figure 1 ) was referred to us for assessment for future prenatal screening having an affected child already. Unusually this family was informative for all the polymorphic restriction enzyme sites analysed (Figure 3) . Using the RS2.0 probe the affected father was apparently homozygous for the 1.75 kb allele (Figure 3b ) which was unusual in that his father II.1 did not carry this allele. His mother was not available for analysis. At first, we considered non-paternity as an explanation until patient 111.1 was shown apparently not to have inherited an allele from his father also ( Figure  3b) . The same pattern of inheritence was shown for the RB1.20 locus (Figure 3a) . 11.1 was heterozygous however for BamHI (Figure 3c ) and XbaI (Figure 3d ) polymorphisms. It was clear that the predisposing mutation, which originated in 1.1, is a deletion including a part of intron 17 (after the XbaI site) and extending at least to intron 20.
In August 1991 prenatal screening was carried out for II.2 after 11 weeks of pregnancy. The foetus was shown to inherit the normal allele (allele 2) with RB1.20 and all of the other probes from the affected father I.1 (Figure 3) and it is therefore expected to be unaffected.
Discussion
We have followed a cohort of patients, with a family history of Rb, who have received pre-symptomatic genetic screening.
In those cases where prenatal tests were performed, DNA from chorionic villi were used and were obtained after approximately 10 weeks of pregnancy. Post-natal tests are carried out using DNA obtained from either cord blood or whole blood obtained early in the child's life. Sometimes it is difficult to obtain large volumes of blood from newborns. This is not the case with cord blood samples. In cases where families are informative for RB1.20, PRO.6 or M1.8, lack of DNA is not a problem, since these polymorphisms can be identified using PCR within 24 h. However, one of the important probes used in Rb screening, RS2.0, still requires reasonable amounts of DNA (5-10tg) and the results are only available after 4-7 days. Prior to our application of intragenic DNA probes to prenatal screening in Rb families the only other such report was by Cavenee et al. (1986) . In this study markers flanking the RB1 gene were used and met with limited success due to recombination events between marker and Rb locus. Prenatal screening was performed in five Rb families and the likelihood of Rb was predicted in two cases and freedom from disease in three. Two of the cases showed evidence of meiotic recombination and the predictive accuracy in one other was only 70% since only loci distal to the Rb locus were informative. We have previously been able to predict, pre-symptomatically, the development of Rb in two patients (J.C., unpublished data) who were carriers of chromosome 13 deletions and who were identified using esterase-D measurements in the series described by Cowell et al. (1989) . In both cases the referral for testing was warranted because of the presence of other congenital abnormalities and dysmorphology which are frequently associated with 13q14 deletions. Both patients eventually developed Rb, before 12 months, although it should be noted that not all such cases develop tumours Wilson et al., 1987) .
Our current series represents the first reported cases of presymptomatic predictions which have been followed for sufficient time to be sure that the prediction was accurate. The majority of familial cases present before 2 years and we have followed four patients for at least this period although, since in fact, the mean age of onset is 14 months six have reached this age disease free. A surprising result was that, to date, all but one of the patients were shown not to have inherited the mutant RB1 gene. There is still a small possibility, however, that intragenic recombination might have occurred. The RB1 gene consists of 27 exons spanning approximately 200 kb of genomic DNA (Friend et al., 1987; McGee et al., 1989) . Assuming the generally accepted recombination frequency of 1 cross-over per 106 base pairs, the theoretical chances of recombination occurring within the RB1 gene is 0.2, or 1:500. To date there have been no cases of recombination in any of the families reported so far (Wiggs et al., 1988; Scheffer et al., 1989; Onadim et al., 1990) which surveyed approximately 140 meioses. The M1.8 unique sequence DNA probe is located in the first exon of RB1 (Bookstein et al., 1988 ) and a VNTR locus occurring in the 3' intron adjacent to exon 20 (McGee et al., 1989) which covers most of the gene (75%). If mutations can occur equally along the length of the gene, as appears to be the case at present Dunn et al., 1989) , the possibility of a predictive error is decreased accordingly if patients are informative at these loci. Given this low chance of intragenic recombination it must be concluded that it is unnecessary to repeatedly screen patients shown not to have inherited the predisposing mutation following linkage analysis.
In one of the families we described, RBF29, the predisposing mutation itself was identified and III.5 was found not to carry this mutation proving our prediction using polymorphic probes. Identification of the actual mutations require the use of different techniques. Only gross structural rearrangements and large deletions are detected by Southern blot analysis. The majority of Rb mutations, however, are small deletions or point mutations which require the use of techniques such as SSCP (single strand conformation polymorphism) and PCR sequencing. Using a combination of these techniques, it is now theoretically possible to identify predisposing mutations in most Rb families and indeed to search for predisposing mutations in constitutional DNA of sporadic patients to determine whether or not they carry a germ-line mutation. However, this approach is very expensive and time consuming and, at present, it is not practical to analyse every patient with Rb, although this situation might improve in the future with the availability of quicker techniques and automated sequencing.
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